Evidence map›Paper›PMID 33638304›Full record

ArticleChemical biology & drug design2021

Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives.

Shahinda S R Alsayed, Shichun Lun, Alan Payne, William R Bishai, Hendra Gunosewoyo

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemical biology & drug design, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shahinda S R AlsayedSchool of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.
Shichun LunDivision of Infectious Disease, Department of Medicine, Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Alan PayneSchool of Molecular and Life Sciences, Curtin University, Perth, WA, Australia.
William R BishaiDivision of Infectious Disease, Department of Medicine, Center for Tuberculosis Research, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Hendra GunosewoyoSchool of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.

Funding

Mycobacterium tuberculosis Survival Regulatory GenesR01AI037856 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BISHAI, WILLIAM RAMSES · 1997 to 2020
$7.2M
Aberrant immune activation in the tuberculosis granuloma: a pivotal role in necrosisR01HL133190 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BISHAI, WILLIAM RAMSES, KRAMNIK, IGOR · 2016 to 2019
$3.0M
Australian Research CouncilNHLBI NIH HHS R01 HL133190NIAID NIH HHS R01 AI037856NIH HHS
6 · The paper itself

Abstract

Several rationally designed isoniazid (INH), pyrazinamide (PZA) and ciprofloxacin (CPF) derivatives were conveniently synthesized and evaluated in vitro against H37Rv Mycobacterium tuberculosis (M. tb) strain. CPF derivative 16 displayed a modest activity (MIC = 16 µg/ml) and was docked into the M. tb DNA gyrase. Isoniazid-pyrazinoic acid (INH-POA) hybrid 21a showed the highest potency in our study (MIC = 2 µg/ml). It also retained its high activity against the other tested M. tb drug-sensitive strain (DS) V4207 (MIC = 4 µg/ml) and demonstrated negligible cytotoxicity against Vero cells (IC

Indexed as

AnimalsAntitubercular AgentsBinding SitesCatalytic DomainCell SurvivalChlorocebus aethiopsCiprofloxacinDNA GyraseDrug DesignDrug Resistance, BacterialIsoniazidMicrobial Sensitivity TestsMolecular ConformationMolecular Docking SimulationMycobacterium tuberculosisNontuberculous MycobacteriaAntitubercular AgentsCiprofloxacinDNA GyraseIsoniazidPyrazinamideciprofloxacinhybrid moleculesindoleamidesisoniazidpyrazinamidetuberculosis

Identifiers

PMID33638304
PMCPMC8113106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.